Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 11/20 | 0.59 |
| ▸ | GSK3B | P49841 | 4/20 | 0.59 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | WNT1 | P04628 | 4/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2086272 | 0.99 | DYRK1A (0.58) | DYRK1AGSK3BUSP30RIPK1PAK1 | |
| SCHEMBL2086672 | 0.93 | DYRK1A (0.69) | DYRK1AGSK3BWNT1 | |
| SCHEMBL3376134 | 0.89 | DYRK1A (0.65) | DYRK1AGSK3BWNT1 | |
| SCHEMBL2089178 | 0.89 | DYRK1A (0.65) | DYRK1AGSK3BWNT1 | |
| Formic Acid SCHEMBL2086893 | 0.86 | DYRK1A (0.61) | DYRK1AGSK3BWNT1 | |
| SCHEMBL2088901 | 0.84 | DYRK1A (0.60) | DYRK1AGSK3BUSP30RIPK1PAK1 | |
| SCHEMBL2086515 | 0.83 | DYRK1A (0.65) | DYRK1AGSK3BUSP30RIPK1WNT1 | |
| SCHEMBL2087204 | 0.83 | DYRK1A (0.57) | DYRK1AGSK3BUSP30RIPK1PAK1 | |
| SCHEMBL2087526 | 0.83 | DYRK1A (0.57) | DYRK1AGSK3BUSP30RIPK1PAK1 | |
| SCHEMBL2087530 | 0.83 | DYRK1A (0.57) | DYRK1AGSK3BUSP30RIPK1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110935028-B | Combined medicine for resisting heart failure and application thereof | 合肥康诺生物制药有限公司 | 2020-11-10 | — | — | CN | claimed |
| EP-1742944-B1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2010-11-10 | — | — | EP | claimed |
| US-20050250808-A1 | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICAL CORPORATION | 2005-11-10 | — | — | US | claimed |
| WO-2023181045-A1 | PROCESS FOR THE PREPARATION OF CARCINOGENIC AZIDO IMPURITIES FREE LOSARTAN AND SALTS THEREOF | IOL CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2023-09-28 | — | — | WO | disclosed |
| CN-112716951-A | Solid pharmaceutical composition comprising amlodipine and losartan | 韩美药品株式会社 | 2021-04-30 | — | — | CN | disclosed |
| CN-107018650-B | Solid pharmaceutical composition comprising amlodipine and losartan | 韩美药品株式会社 | 2021-02-02 | — | — | CN | disclosed |
| CN-110935028-B | Combined medicine for resisting heart failure and application thereof | 合肥康诺生物制药有限公司 | 2020-11-10 | — | — | CN | disclosed |
| CN-110935028-A | Combined medicine for resisting heart failure and application thereof | 合肥康诺药物开发有限公司 | 2020-03-31 | — | — | CN | disclosed |
| US-10034862-B2 | Solid pharmaceutical composition comprising amlodipine and losartan | HANMI PHARM. CO., LTD. (KR) | 2018-07-31 | — | — | US | disclosed |
| US-20170326110-A1 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE AND LOSARTAN | HANMI PHARM. CO., LTD. (KR) | 2017-11-16 | — | — | US | disclosed |
| WO-2016052866-A1 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE AND LOSARTAN | HANMI PHARM. CO., LTD. (KR) | 2016-04-07 | — | — | WO | disclosed |
| US-7271269-B2 | Stability, purity, potassium salt of losartan in crystal Form X, as anti-hypertensive agent | LEK PHARMACEUTICALS D.D. (SI) | 2007-09-18 | — | — | US | disclosed |
| US-20060004207-A1 | Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods | LEK PHARMACEUTICALS D.D. (SI) | 2006-01-05 | — | — | US | disclosed |
| US-20050250808-A1 | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICAL CORPORATION | 2005-11-10 | — | — | US | disclosed |
| EP-1589966-A2 | PREPARATION OF NEW PHARMACEUTICALLY SUITABLE SALT OF LOSARTAN AND FORMS THEREOF WITH NEW PURIFICATION AND ISOLATION METHODS | LEK Pharmaceuticals D.D. (SI) | 2005-11-02 | — | — | EP | disclosed |
| EP-1458693-A4 | AMORPHOUS AND CRYSTALLINE FORMS OF LOSARTAN POTASSIUM AND PROCESS FOR THEIR PREPARATION | TEVA PHARMA (IL) | 2005-02-09 | — | — | EP | disclosed |
| EP-1458693-A1 | AMORPHOUS AND CRYSTALLINE FORMS OF LOSARTAN POTASSIUM AND PROCESS FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004066997-A2 | PREPARATION OF NEW PHARMACEUTICALLY SUITABLE SALT OF LOSARTAN AND FORMS THEREOF WITH NEW PURIFICATION AND ISOLATION METHODS | LEK PHARMACEUTICALS D.D. (SI) | 2004-08-12 | — | — | WO | disclosed |
| US-20040006237-A1 | Amorphous and crystalline forms of losartan potassium and process for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-01-08 | — | — | US | disclosed |
| WO-2003048135-A1 | AMORPHOUS AND CRYSTALLINE FORMS OF LOSARTAN POTASSIUM AND PROCESS FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250808-A1 | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA2 | DYRK1A 1558/4885GSK3B 920/4885USP30 3786/4885 |
| US-20040006237-A1 | Amorphous and crystalline forms of losartan potassium and process for their preparation | REN, AGTR1, AGT | DYRK1A 1047/4885GSK3B 2944/4885USP30 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.